摘要
目的:观察黄芪甲苷与川芎嗪合用对大鼠脑缺血再灌注损伤保护的作用。方法:采用大鼠大脑中动脉局灶性栓塞(MCAO)模型,观察对各用药组大鼠脑缺血损伤后神经功能,脑梗死体积,脑含水量、脑指数,缺血侧脑组织超氧化物歧化酶(SOD)活力、丙二醛(MDA)含量,Bcl-2和Bax蛋白表达,以及尼氏小体数的影响。结果:黄芪甲苷与川芎嗪合用可显著地减轻MCAO模型大鼠的神经功能缺损(P<0.01);显著缩小脑梗死体积(P<0.01);降低脑含水量和脑指数(P<0.01);显著提高脑组织SOD活性(P<0.01),明显降低MDA含量(P<0.01);上调Bcl-2蛋白(P<0.01),下调Bax蛋白表达(P<0.01);显著抑制尼氏小体的减少或消失(P<0.01)。且两者合用的作用明显优于单用。结论:黄芪甲苷与川芎嗪合用对大鼠脑缺血性损伤具有明显的保护作用。
Objective： To observe the protective effects of compatibility of astragaloside A with ligustrazine on cerebral ischemia and reperfusion injury. Methods： By using focal middle cerebral artery embolization （MCAO） model, to observe the targets including symptoms of neurological deficit score, infarct volume, brain index and brain water content, activity of SOD and content of MDA of ischemic brain tissue, Bcl-2 and Bax protein expression, and quantity of nissl body. Results： Astragaloside A and ligusa＇azine could significantly reduce the symptoms of neurological deficits （P〈0.01）; narrow infarct volume of brain tissue obviously （P〈0.01）; reduce brain index and brain water （P〈0.01）; raise activity of SOD and reduce content of MDA （P〈0.01）; increase Bcl-2 protein （P〈0.01）, reduce Bax expression （P〈0.01）; inhibit reducing or disappearing of nissl body （P〈0.01）. The effects of the compatibility of astragaloside A with ligustrazine was better than the single-purpose. Conclusion： The compatibility of astragaloside A with ligustrazine have significant protective effects on ischemic brain injury.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2013年第9期2788-2792,共5页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金(No.81202636
No.81274176
No.81173647)
浙江省自然科学基金(No.Z2101201
No.LR12H27001)
浙江省科技厅项目(No.2011C23039)
高等学校博士学科点专项科研基金资助课题(No.20103322120003)
浙江省中管局项目(No.2011ZQ007)
浙江省中医药重点学科(No.2012-XK-A06)
浙江省卫生高层次创新人才培养项目~~
关键词
黄芪甲苷
川芎嗪
脑缺血再灌注
保护作用
大脑中动脉局灶性栓塞模型
Astragaloside A
Ligustrazine
Cerebral ischemia and reperfusion
Protective effect
Middle cerebral artery embolization model
